HormonesReview ArticlePaywall

Thyroid Disorders in Older Adults Need Slower Dosing and Higher TSH Targets

A geriatric review urges start-low, go-slow levothyroxine and higher TSH targets in older adults to avoid atrial fibrillation, bone loss, and fractures.

Wednesday, November 18, 2026 0 views
Published in Clin Geriatr Med
a physician performing a neck thyroid ultrasound on an elderly woman in a clinic exam room

Summary

Thyroid problems are among the most common hormone disorders in older adults, but they are easy to miss or overtreat. With age, the brain-thyroid hormone feedback loop shifts, and symptoms often look different from those in younger people. This review covers diagnosis and management. For underactive thyroid, both overt and subclinical, the authors recommend starting levothyroxine at a low dose and increasing slowly, aiming for higher thyroid-stimulating hormone (TSH) targets than in younger adults. This helps avoid iatrogenic overtreatment, which can cause an overactive thyroid state, atrial fibrillation, bone loss, and fractures. Overactive thyroid, including the apathetic form and amiodarone-induced disease, can harm the heart and skeleton and needs prompt recognition. Thyroid nodules and cancer call for risk-stratified, ultrasound-based evaluation. Throughout, care should fit each person's function, other illnesses, and goals. This summary is based on the abstract only.

0:00--:--

Detailed Summary

Thyroid dysfunction is among the most common endocrine disorders in older adults, yet it is hard to diagnose and manage well. Age-related shifts in the hypothalamic-pituitary-thyroid axis and atypical symptoms raise the risk of both underdiagnosis and overtreatment. For people who care about healthspan, thyroid hormone status touches the heart, bones, and overall function.

This narrative review from geriatric medicine authors, published in Clinics in Geriatric Medicine, surveys diagnostic and management considerations for thyroid disorders in older patients. According to the abstract, it covers hypothyroidism, hyperthyroidism, and thyroid nodules and malignancy.

For hypothyroidism, both overt and subclinical, which is the more common condition, the authors advise a start low, go slow levothyroxine approach with higher TSH targets than those used in younger adults. The aim is to avoid iatrogenic thyrotoxicosis, atrial fibrillation, bone loss, and fractures. For hyperthyroidism, including apathetic presentations and amiodarone-induced forms, the review stresses cardiovascular and skeletal consequences that require prompt recognition and treatment. Thyroid nodules and malignancy should be evaluated with risk-stratified, ultrasound-based assessment.

The overarching message is a patient-centered, geriatric-informed approach tailored to function, comorbidities, and goals of care. In practice, that means avoiding automatic treatment to a younger-adult TSH range and watching for harms of overreplacement, as well as for missed disease in patients whose symptoms are subtle.

Caveats: this is a review, not a new trial, and only the abstract was available, so specific TSH targets, dosing details, evidence grading, and the strength of the underlying studies cannot be assessed here. Readers should consult the full text and current guidelines. Individual decisions belong with a clinician who knows the patient's cardiac, bone, and overall health.

Key Findings

  • Hypothyroidism, overt and subclinical, predominates in older adults and warrants start-low, go-slow levothyroxine dosing.
  • Higher TSH targets are recommended in older adults to avoid iatrogenic thyrotoxicosis, atrial fibrillation, bone loss, and fractures.
  • Hyperthyroidism, including apathetic and amiodarone-induced forms, carries cardiovascular and skeletal consequences needing prompt treatment.
  • Thyroid nodules and malignancy call for risk-stratified, ultrasound-based evaluation.
  • Age-related axis shifts and atypical presentations raise risks of both underdiagnosis and overtreatment.

Methodology

This is a narrative review in a geriatric medicine journal. The abstract does not describe search methods, number of studies, or evidence grading. No new data are reported in the abstract.

Study Limitations

This summary is based on the abstract only, as the full text is not open access. Specific TSH targets, dosing schedules, and the quality of supporting evidence are not given in the abstract. As a narrative review, it may reflect author selection of studies and expert opinion.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: